Floatz logo

Cynk-001

Giant Cell Glioblastoma

Celularity IncorporatedCell therapyPhase 1/2Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Giant Cell Glioblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Case Comprehensive Cancer Center
Phase 2BBB
Cediranib
Lawrence Recht
Phase 2BBB
Temsirolimus
National Cancer Institute (NCI)
Phase 2BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BB
Rindopepimut
Celldex Therapeutics
Phase 3BB

View all 50 →

Same molecule, other indications

Cynk-001 is also rated in:

glioblastomaDormant
C
Indicative ·
37 / 100
View asset →
monoclonal paraproteinemia diseaseDormant
D
Indicative ·
30 / 100
View asset →
neoplasmDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →